TY - JOUR
T1 - Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons
AU - Berg, Kelly A.
AU - Rowan, Matthew P.
AU - Gupta, Achla
AU - Sanchez, Teresa A.
AU - Silva, Michelle
AU - Gomes, Ivone
AU - McGuire, Blaine A.
AU - Portoghese, Philip S.
AU - Hargreaves, Kenneth M.
AU - Devi, Lakshmi A.
AU - Clarke, William P.
PY - 2012/2
Y1 - 2012/2
N2 - The peripheral δ opioid receptor (DOR) is an attractive target for analgesic drug development. There is evidence that DOR can form heteromers with the κ-opioid receptor (KOR). As drug targets, heteromeric receptors offer an additional level of selectivity and, because of allosteric interactions between protomers, functionality. Here we report that selective KOR antagonists differentially altered the potency and/or efficacy of DOR agonists in primary cultures of adult rat peripheral sensory neurons and in a rat behavioral model of thermal allodynia. In vitro, the KOR antagonist nor-binaltorphimine (nor-BNI) enhanced the potency of [D-Pen 2,5]-enkephalin (DPDPE), decreased the potency of [D-Ala 2, D-Leu 5]- enkephalin (DADLE), and decreased the potency and efficacy of 4-[(R)-[(2S,5R)-4-allyl-2,5- dimethylpiperazin-1-yl](3-methoxyphenyl) methyl]-N, N-diethylbenzamide (SNC80) to inhibit prostaglandin E 2 (PGE 2)-stimulated adenylyl cyclase activity. In vivo, nor-BNI enhanced the effect of DPDPE and decreased the effect of SNC80 to inhibit PGE 2-stimulated thermal allodynia. In contrast to nor-BNI, the KOR antagonist 5′-guanidinonaltrindole (5′-GNTI) reduced the response of DPDPE both in cultured neurons and in vivo. Evidence for DOR-KOR heteromers in peripheral sensory neurons included coimmunoprecipitation of DOR with KOR, a DOR-KOR heteromer selective antibody augmented the antinociceptive effect of DPDPE in vivo, and the DOR-KOR heteromer agonist 6′-GNTI inhibited adenylyl cyclase activity in vitro as well as PGE 2-stimulated thermal allodynia in vivo. Taken together, these data suggest that DOR-KOR heteromers exist in rat primary sensory neurons and that KOR antagonists can act as modulators of DOR agonist responses most likely through allosteric interactions between the protomers of the DOR-KOR heteromer.
AB - The peripheral δ opioid receptor (DOR) is an attractive target for analgesic drug development. There is evidence that DOR can form heteromers with the κ-opioid receptor (KOR). As drug targets, heteromeric receptors offer an additional level of selectivity and, because of allosteric interactions between protomers, functionality. Here we report that selective KOR antagonists differentially altered the potency and/or efficacy of DOR agonists in primary cultures of adult rat peripheral sensory neurons and in a rat behavioral model of thermal allodynia. In vitro, the KOR antagonist nor-binaltorphimine (nor-BNI) enhanced the potency of [D-Pen 2,5]-enkephalin (DPDPE), decreased the potency of [D-Ala 2, D-Leu 5]- enkephalin (DADLE), and decreased the potency and efficacy of 4-[(R)-[(2S,5R)-4-allyl-2,5- dimethylpiperazin-1-yl](3-methoxyphenyl) methyl]-N, N-diethylbenzamide (SNC80) to inhibit prostaglandin E 2 (PGE 2)-stimulated adenylyl cyclase activity. In vivo, nor-BNI enhanced the effect of DPDPE and decreased the effect of SNC80 to inhibit PGE 2-stimulated thermal allodynia. In contrast to nor-BNI, the KOR antagonist 5′-guanidinonaltrindole (5′-GNTI) reduced the response of DPDPE both in cultured neurons and in vivo. Evidence for DOR-KOR heteromers in peripheral sensory neurons included coimmunoprecipitation of DOR with KOR, a DOR-KOR heteromer selective antibody augmented the antinociceptive effect of DPDPE in vivo, and the DOR-KOR heteromer agonist 6′-GNTI inhibited adenylyl cyclase activity in vitro as well as PGE 2-stimulated thermal allodynia in vivo. Taken together, these data suggest that DOR-KOR heteromers exist in rat primary sensory neurons and that KOR antagonists can act as modulators of DOR agonist responses most likely through allosteric interactions between the protomers of the DOR-KOR heteromer.
UR - http://www.scopus.com/inward/record.url?scp=84863393062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863393062&partnerID=8YFLogxK
U2 - 10.1124/mol.111.072702
DO - 10.1124/mol.111.072702
M3 - Article
C2 - 22072818
AN - SCOPUS:84863393062
SN - 0026-895X
VL - 81
SP - 264
EP - 272
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 2
ER -